Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Artra Group's revenue for the
three
months ended in Jun. 2026 was 円0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was 円3,918 Mil.
Artra Group's Revenue per Share for the
three
months ended in Jun. 2026 was 円0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was 円381.60.
Warning Sign:
Artra Group Corp revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Artra Group was 4.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -7.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 2.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Artra Group's highest 3-Year average Revenue per Share Growth Rate was 18.40% per year. The lowest was -13.50% per year. And the median was 8.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Artra Group Revenue Related Terms
Artra Group Revenue Historical Data
* Premium members only.
The historical data trend for Artra Group's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Artra Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artra Group Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Artra Group's Revenue distribution charts can be found below:
* The bar in red indicates where Artra Group's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,918 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artra Group (TSE:6029) has a Revenue of 円3,918 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Artra Group and its competitors.
Is Artra Group's Revenue too high?
Artra Group's current Revenue is 円3,918 Mil. Overall, Artra Group has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Artra Group's Revenue compare to HCA and THC?
Artra Group's Revenue of 円3,918 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Artra Group and its competitors. Artra Group's current Revenue is 円3,918 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artra Group stock overvalued right now?
Based on GuruFocus' analysis, Artra Group (TSE:6029) is currently considered Significantly Overvalued. The stock's GF Value™ is 円116.04, compared to a current price of 円190.00 — trading 63.7% above its estimated fair value. The current Revenue is 円3,918 Mil. Artra Group's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Artra Group (TSE:6029), the current Revenue is 円3,918 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artra Group (TSE:6029) Overvalued in 2026?
Based on GuruFocus' analysis, Artra Group stock appears to be overvalued.
The current stock price of 円190.00 is trading 63.7% above its estimated GF Value™ of 円116.04.
GuruFocus considers Artra Group to be Significantly Overvalued.
Key valuation signals for TSE:6029:
Revenue: 円3,918 Mil
GF Value™: 円116.04 vs. price of 円190.00 (63.7% above fair value)
No single metric tells the full story. See the TSE:6029 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artra Group Corp is engaged in the healthcare support business, providing services that assist the operation and management of clinics and related facilities. The group has two reportable segments: Acupuncture & Orthopedic Clinic Support and Toy Sales Business. The Acupuncture and Orthopedic Clinic Support segment is involved in supporting acupuncture and orthopedic clinics through services such as bone setting chains, provision of equipment and consumables, Attra billing services, HONEY-STYLE, and nursing care support. The Toy Sales segment focuses on the sale of toys, stationery, and other related products.
52GF Score
Get the complete analysis for TSE:6029
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6029 has been successfully added to your 
